Olema Pharmaceuticals (Olema Oncology) is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and related hormone-driven cancers. Its lead candidate, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist and selective estrogen receptor degrader in late-stage trials for ER-positive, HER2-negative metastatic breast cancer. The company builds on expertise in endocrine-driven tumors, nuclear receptors, and mechanisms of treatment resistance.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -43.8 | — |
| Q3 2025 | 0 | — | -42.2 | — |
| Q4 2025 | 0 | — | -46.1 | — |
| Q1 2026 | 0 | — | -53.1 | — |
| Q2 2026 | 0 | — | -63.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Churchill Capital Corp XII (CXII), Bridgewater Bancshares, Inc. (BWB), OrthoPediatrics Corp. (KIDS), SOPHiA GENETICS SA (SOPH), Shenandoah Telecommunications Company (SHEN), DBV Technologies S.A. (DBVT)